Parabilis Sets Biotech IPO Record - Takeaways - MDSpire

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

June 15, 2026
2 min

The Medicine Maker

Share

1

Parabilis Medicines raised $670 million in an IPO, setting a new record for biotech listings on Nasdaq.
2

The company sold 33.5 million shares at $20 each and began trading under the ticker PBLS on June 10.
3

Parabilis plans to use IPO proceeds to advance its stabilized helical peptide platform and cancer pipeline.
4

The company is developing zolucatetide, targeting various solid tumors with Wnt pathway-activating mutations.
5

Parabilis also secured a $75 million private placement with Regeneron Pharmaceuticals, enhancing its financial backing.